References

vestich

Известия Национальной академии наук Беларуси. Серия химических наук

Proceedings of the National Academy of Sciences of Belarus, Chemical Series

1561-83312524-2342

The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"

vestich-183

Research Article

Статьи

Дизайн, синтез и биологические свойства ингибиторов ВСR-ABL тирозинкиназы, применяемых для лечения хронического миелолейкоза

Design, synthesis and biological properties of BCR-ABL tyrosine kinase inhibitors used for chronic myelogenous leucemia treatment

Фарина

А. В.

Farina

A. V.

noemail@neicon.ru

Калиниченко

Е. Н.

Kalinichenko

E. N.

kalinichenko@iboch.bas-net.by

Институт биоорганической химии НАН БеларусиInstitute of Bioorganic Chemistry of the National Academy of Sciences of Belarus

2016

08062016

01105121

2016

Фарина А.В., Калиниченко Е.Н.

Farina A.V., Kalinichenko E.N.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://vestichem.belnauka.by/jour/article/view/183

Эффективность лечения хронического миелолейкоза существенно повысилась после введения в клиническую практику иматиниба - селективного ингибитора BCR-ABL тирозинкиназы. Описаны история разработки иматиниба, методы его синтеза и направления дальнейшей оптимизации структуры.

Imatinib, a selective BCR-ABL tyrosine kinase inhibitor has significantly improved efficacy of chronic myelogenous leukemia treatment. This review focuses on discovery and development of imatinib, methods of its synthesis and further structure optimization opportunities.

иматинибингибиторы тирозинкиназыхронический миелоидный лейкозimatinibtyrosine kinase inhibitorschronic myelogenous leukemia

References1

Fialkow, P. J. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage / P. J. Fialkow, R. J. Jacobson, T. Papayannopoulou // Am J Med. - 1977. - Vol. 63, № 1. -P. 125-130.

BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death / A. McGahon [et al.]// Blood. - 1994. - Vol. 83, N 12. - P. 1179-1187.

Williams hematology, 6th ed. / E. Beutler [et al.]. - New York: McGraw-Hill, 2001.

Nowell, P. A minute chromosome in human chronic granulocytic leukemia / P. Nowell, D. A. Hungerford // Science. -1960. - Vol. 142. - P. 1497.

Nowell, P. C. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia / P. C. Nowell, D. A. Hungerford // J. Natl. Cancer Inst. - 1961. - Nov. Vol. 27. - P. 1013-1035.

Rowley, J. D. A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining / J. D. Rowley // Nature. - 1973. - Vol. 243, N 5405. - P. 290-293.

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products / T. G. Lugo [et al.] // Science. -1990. - Vol. 247 - P. 1079-1082.

Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics / R. Kurzrock [et al.] // Ann Intern Med. - 2003. - Vol. 138, N 10. - P. 819-830.

Tumors of Haematopoietic and Lymphoid Tissues / J. W. Vardiman [et al.] - Lyon: IARCPress, 2009. - P. 15-59.

Savage, D. G. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period / D. G. Savage, R. M. Szydlo, J. M. Goldman // Br. J. Haematol. - 1997. - Vol. 96. - P. 111-116.

Kantarjian, H. M. Chronic myelogenous leukemia: a concise update / H. M. Kantarjian [et al.] // Blood. - 1993. -Vol. 82. - P. 691-703.

Kantarjian, H. M. Definition of the accelerated phase of chronic myelogenous leukemia (letter) / H. M. Kantarjian, M. Talpaz // J. Clin. Oncol. - 1988. - Vol. 6. - P. - 180-182.

Kantarjian, H. M. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients / H. M. Kantarjian [et al.] // Am. J. Med. - 1987. - Vol. 83. - P. 445-454.

Goldman, J. M. Chronic myeloid leukemia: current treatment options / J. M. Goldman, B. J. Druker // Blood. - 2001. -Vol. 98. - P. 2039-2042.

Cortes, J. E. Chronic myelogenous leukemia: a review / J. E. Cortes, M. Talpaz, H. Kantarjian// Am. J. Med. - 1996. -Vol. 100, N 5. - P. 555-570.

Clinical investigation of human alpha interferon in chronic myelogenous leukemia /M. Talpaz[et al.] // Blood. - 1987. -Vol. 69, N 5. - P. 1280-1298.

Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials / Chronic Myeloid Leukemia Trialists' Collaborative Group // J. Natl. Cancer Inst. - 1997. - Vol. 89, N 21. - P. 1616-1620.

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service / H. M. Kantarjian [et al.] // Ann. Intern. Med. - 1995. - Vol. 122. - P. 254-261.

Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine // H. M. Kantarjian [et al.] // J. Clin. Oncol. - 1999. - Vol. 17. - P. 284-292.

Talpaz, M. The interferon-alpha revival in CML / M. Talpaz, J. Mercer, R. Hehlmann// Ann. Hematol. - 2015. - Vol. 94, Suppl 2. - P. 195-207.

Approval summary for imatinibmesylate capsules in the treatment of chronic myelogenous leukemia / M. H. Cohen [et al.] // Clin. Cancer Res. - 2002. - Vol. 8, N 5. - P. 935-942.

Approval summary: imatinibmesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase / J. R. Johnson [et al.] //Clin. Cancer Res. - 2003. - Vol. 9, N 6. - P. 1972-1979.

Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials / L. Roy [et al.] // Blood. - 2006. - Vol. 108, N 5. - P. 1478-1484.

International randomized study of interferon vs STI571 (IRIS) 8-year follow uP. sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib / M. Deininger [et al.] // Blood. - 2009. - Vol. 114. - P. 1126.

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience / H. Kantarjian [et al.] // Blood. - 2012. - Vol. 119, N 9. - P. 1981-1987.

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. M. Talpaz [et al.] // Blood. - 2002. - Vol. 99. - P. 1928-1937.

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study / C. L. Sawyers [et al.] // Blood. - 2002. - Vol. 99. - P. 3530-3539.

Evolution of therapies for chronic myelogenous leukemia / F. P. Santos [et al.] // Cancer J. - 2011. - Vol. 17. N 6 - P. 465-476.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia / S. G. O'Brien [et al.] // N. Engl. J. Med. - 2003. - Vol. 348. - P. 994-1004.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia / B. J. Druker [et al.] // N. Engl. J. Med. - 2006. - Vol. 355. - P. 2408-2417.

Jabbour, E. Use of Second- and Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm / E. Jabbour, H. Kantarjian, J. Cortes //Clin. Lymphoma Myeloma. Leuk. - 2015. -Vol. 15, N 6. - P. 323-334.

A review of the European LeukemiaNet recommendations for the management of CML / M. Baccarani [et al.] // Ann. Hematol. - 2015. - Vol. 94, Suppl 2. - P. 141-147.

Chronic myelogenous leukemia: a review and update of therapeutic strategies / G. Garcia-Manero [et al.] // Cancer. -2003. - Vol. 98, N 3. - P. 437-457.

Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia / R. Hehlmann [et al.] // Blood. - 2007. - Vol. 109, N 11. - P. 4686-4692.

Leitner, A. A. Current treatment concepts of CML. / A. A. Leitner, A. Hochhaus, M. C. Muller // Curr. Cancer Drug. Targets. - 2011. - Vol. 11, N 1. - P. 31-43.

Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphos-tins / M. Anafi [et al.] // J. Biol. Chem. - 1992. - Vol. 267, N 7. - P. 4518-4523.

Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycinA / Y. Uehara [et al.] // Virology. -1988. - Vol. 164, N 1. - P. 294-298.

Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC) / J. Zimmermann [et al.] // Arch. Pharm. - 1996. - Vol. 329, N 7. - P. 371-376.

Phenylamino-pyrimidine (PAP)-derivatives: a new class of potent and highly selective PDGF-receptor autophos-phorylation inhibitors / J. Zimmermann [et al.] // Bioorg. MedChem. Lett. - 1996. - Vol. 6. - P. 1221-1226.

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug / R. Capdeville [et al.] // Nat. Rev. Drug Discov. - 2002. - Vol. 1, N 7. - P. 493-502.

Deininger, M. The development of imatinib as a therapeutic agent for chronic myeloid leukemia / M. Deininger, E. Buchdunger, B. J. Druker // Blood. - 2005. - Vol. 105, N 7 - P. 2640-2653.

Pyrimidine derivatives and processes for the preparation thereof: US Pat. 5521184 / J. Zimmermann; датапубл.: 28.05.1996.

N-phenyl-2-pyrimidine-amine derivatives: world pat. WO2003066613 / O. Loiseleur [et al.]; дата публ.: 14.08.2003.

The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib / B. J. Deadman [et al.] // Org. Biomol. Chem. - 2013. - Vol. 11, N 11. - P. 1766-800.

A practical synthesis of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid-the key precursor toward imatinib / E. V. Koroleva [et al.] // Tetrahedron Letters. - 2012. - Vol. 53. - P. 5056-5058.

Способ получения метансульфоната 4-[(4-метил-1-пиперазинил)-метил]-N-[4-метил-3-{[4-(3-пиридил)-2-пиримидинил]-амино}фенил]бензамида: пат. 17047 Респ. Беларусь / В. Е. Агабеков [и др.]; дата публ.: 30.04.2013.

Способ получения метилового эфира и дигидрохлорида 4-[(4-метилпиперазин-1-ил)метил]-бензойной кислоты: пат. 17842 Респ. Беларусь / Е. В. Королева [и др.]; дата публ.: 30.12.2013.

Managementofimatinib-resistantpatientswithchronicmyeloidleukemia / P. K. Bhamidipati [etal.] //Ther. Adv. Hematol. - 2013. - Vol. 4, N 2. - P. 103-117.

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib / T. Ernst [et al.] // Haematologica. - 2008. - Vol. 93, N 2. - P. 186-192.

Eck, M. J. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl / M. J. Eck, P. W. Manley // Curr. Opin. Cell. Biol. - 2009. - Vol. 21, N 2. - P. 288-295.

Lee, F. Overcoming kinase resistance in chronic myeloid leukemia / F. Lee, A. Fandi, M. Voi // Int. J. Biochem. Cell Biol. - 2008. - Vol. 40, N 3. - P. 334-343.

Ravandi, F. Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors / F. Ravandi //Clin. Lymphoma Myeloma Leuk. - 2011. - Vol. 11, N 2. - P. 198-203.

Valent, P. Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches / P. Valent // Biologics. - 2007. - Vol. 1, N 4. - P. 433-448.

FDA approval for nllotlnlb [Электронныйресурс] /US National Institutes of Health, National Cancer Institute. - Режим доступа: httP.//www.cancer.gov/about-cancer/treatment/drugs/fda-nilotinib. - Дата доступа: 18.03.2015.

Deremer, D. L. Nilotinib: a second-cgeneration tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia / D. L. Deremer, C. Ustun, K. Natarajan // Clin. Ther. - 2008. - Vol. 30, N 11. - P. 1956-1975.

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl / E. Weisberg [et al.] // Cancer Cell. -2005. - Vol. 7, N 2. - P. 129-141.

AMN107: tightening the grip of imatinib / T. O'hare [et al.] // Cancer Cell. - 2005. - Vol. 7, N 2. - P. 117-119.

Jabbour, E. Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review / E. Jabbour, J. Cortes, H. Kantarjian // Core Evid. - 2009. - Vol. 4. - P. 207-213.

Manley, P. W. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia / P. W. Manley, S. W. Cowan- Jacob, J. Mestan // Biochim. Biophys. Acta. - 2005. -Vol. 1754, N 1-2. - P. 3-13.

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. S. Redaelli [et al.] // J. Clin. Oncol. - 2009. - Vol. 27, N 3. - P. 469-471.

Moslehi, J. J. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J. J. Moslehi, M. Deininger // J. Clin. Oncol. - 2015.

Miller, G. D. Resistant mutations in CML and Ph(+)ALL - role of ponatinib / G. D. Miller, B. J. Bruno, C. S. Lim // Biologics. - 2014. - Vol. 8. - P. 243-254.

Comprehensive analysis of the in vitro potency of ponatinib, and all other approved BCR-ABL tyrosine kinase inhibitors (TKIs), against a panel of single and compound BCR-ABL mutants / M. G. Joseph [et al.] // Blood. - 2013. - Vol. 122, N 21. - P. 3992-3992.

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3(trifluo-romethyl) phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant / W. S. Huang [et al.] // J. Med. Chem. - 2010. - Vol. 53, N 12. - P. 4701-4719.

European approval of Ponatinib for leukemia. [Электронный ресурс] / Режим доступа: httр.//news.medlive.cn/all/info-progress/show-50240_112. html - Дата доступа: 18.03.2015.

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history / E. Jabbour // Leukemia. - 2010. - Vol. 24, N 1. - P. 6-12.

Carneiro, B. A. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events / B. A. Carneiro, J. B. Kaplan, F. J. Giles // Expert Rev. Hematol. - 2015. - Vol. 8, N 4. - P. 457-479.

FDA Drug Safety Communication: FDA requires multiple new safety measures for leukemia drug Iclusig; company expected to resume marketing. [Электронный ресур^ United States Food and Drug Administration. - Режим доступа: httр.//www.fda.gov/Drugs/DrugSafety/ucm379554.htm. - Дата доступа: 15.05.2015.

-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation / W. S. Huang [et al.] // J. Med. Chem. - 2009. - Vol. 52, N 15. - P. 4743-4756.

Design, synthesis, and biological activity of phenyl-pyrazole derivatives as BCR-ABL kinase inhibitors / L. Hu [et al.] // Bioorg. Med. Chem. - 2015. - Vol. 23, N 13. - P. 3147-3152.

Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl (T315I) mutant / X. Lu [et al.] // Bioorg. Med. Chem. Lett. - 2015. - Vol. 25, N 17. - P. 3458-3463.

Discovery of novel Bcr-Abl inhibitors with diacylatedpiperazine as the flexible linker /X. Pan // Org. Biomol. Chem. -2015. - Vol. 13, N 25. - P. 7050-7066.

Synthesis of N-Aryl benzamidescontaining pharmacophoric tyrosine kinase inhibitorfragments. E. V. Koroleva [et al.] // Rus. J. Org. Chem. - 2015. - Vol. 51, N 1. - P. 101-109.

Bcr-Abl tyrosine kinase inhibitors: a patent review / A. Desogus [et al.] // Expert Opin. Ther. Pat. - 2015. - Vol. 25, N 4. - P. 397-412.

The authors declare that there are no conflicts of interest present.